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Background: The pharmacoinvasive strategy is ideal for ST elevation myocardial infarction patients (STEMI pts) arriving at hospitals unable to 
offer timely primary percutaneous coronary intervention (PCI). The optimal timing of coronary angiography (angio) after fibrinolysis and its impact on 
clinical outcomes is uncertain.
Methods: Patient level data from 6/7 trials (with median time to angio <12 hrs) of STEMI pts receiving fibrinolysis and randomized to early angio 
were included in a collaborative pt level analysis (SIAM III, GRACIA 1, CAPITAL AMI, WEST, CARESSinAMI, TRANSFER AMI, and NORDISTEMI). The primary 
endpoint was 30 day death or re-MI. A key secondary endpoint was in-hospital TIMI major bleeding. The relationship between treatment delay (time 
from lysis to angio) and outcomes was studied in multivariable models.
Results: Among 1238 pts (median age 59 years, 21% female, 82% Killip class I) randomized to early angio (87% had PCI), the median treatment 
delay was 165 (115, 228) min. Clinical outcomes were examined by treatment delay (Table). Age, presenting heart rate, and Killip class were 
significant independent predictors of 30 day death/re-MI; however, treatment delay per hour was not (HR=1.01, 95% CI=0.94-1.07, p=0.87). 
Outcome
(%)
Overall n=1238
0-2 Hrs
n=349
2-4 Hrs
n=622
>4 Hrs
n=267
p Value for trend
30 days 
Death/re-MI 5.2 4.9 5.8 6.4 0.41
Death 2.9 2.6 3.2 2.6 0.92
re-MI 3.0 2.3 2.9 4.1 0.19
Recurrent Ischemia 4.6 3.7 3.7 7.9 0.02
Stroke 1.0 0.9 1.0 1.1 0.74
In-Hospital
TIMI major Bleeding 4.7 4.6 5.1 3.8 0.68
Conclusions: Treatment delay was not predictive of 30 day death/re-MI among fibrinolytic-treated STEMI pts having early angio. Very early angio
 (< 2 hrs) did not appear to increase the risk of 30 day death/re-MI or in-hospital major bleeding and may reduce recurrent ischemia.
